AEON Biopharma Says FDA Indicated Prior Head-To-Head Studies Vs. Botox Can Be Submitted As Supportive Evidence For ABP-450 Biosimilar
Share
Why It Matters
The FDA said AEON can use old studies comparing their drug to Botox. This makes it easier for AEON to get their new medicine approved.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.